GlassScriptPhysician profile
Lisa M Reed
NPI 1952510588
$11,993.24
in general payments reported to CMS, 2019-2025
27 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,013 · 2022: $2,432 · 2023: $2,319 · 2024: $3,005 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,063 · Education: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.80 |
| Education | $485.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,761.34 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,511.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,210.19 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,193.22 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $749.70 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $605.95 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $557.08 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $511.63 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $355.85 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $330.78 | 2021-2024 | Siliq, Targretin |
| E.R. Squibb & Sons, L.L.C. | $317.78 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $300.66 | 2021-2025 | Adbry |
| Incyte Corporation | $264.11 | 2021-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.82 | 2023-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $213.93 | 2023-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $210.16 | 2021-2024 | |
| Biofrontera INC. | $132.94 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $79.54 | 2021 | |
| Dermavant Sciences, INC. | $78.62 | 2023-2024 | Vtama |
| Organon LLC | $72.64 | 2023-2025 | Hadlima, Vtama |
| Galderma Laboratories, L.P. | $68.17 | 2024-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $61.96 | 2021-2022 | |
| Genentech USA, INC. | $57.78 | 2022-2023 | Xolair |
| Paratek Pharmaceuticals, INC. | $34.20 | 2022-2023 | Nuzyra |
| Almirall LLC | $22.42 | 2023 | Seysara |
| Verrica Pharmaceuticals INC. | $18.90 | 2025 | Ycanth |
| Lnhc, INC | $16.63 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.